HAVCR2 and neoplasm: Moreover, research is also investigating the co-administration of autologous natural killer cells and oncolytic viral adjuvants like TILT-123 or MEM-288 (which is a monoclonal antibody that targets TIM-3) to enhance immune cell activity and improve the anti-tumour response.